Catherine Argyriou, PhD, discusses peroxisome disease and the development of a retinal gene therapy for PEX1-mediated Zellweger Spectrum Disorder.
This webinar provides background on peroxisomal disorders and the PEX1-G844D mouse model for mild Zellweger Spectrum Disorder, which presents with retinal degeneration and vision loss. Dr. Argyriou describes how her team used AAV8-mediated gene delivery to robustly and durably improve functional vision, retinal response, retinal structure, and biochemical metabolites in ZSD mice. Techniques used include subretinal injection, ERG, optomotor testing, histology, immunohistochemistry, and LC-MSMS. AAV vector design and validation are also discussed. This work attracted venture capital investment and is now ready to enter the clinical translation phase.
Key Topics Include:
- Introduction to peroxisome disease and the PEX1-G844D mouse model
- Application of PEX1 gene augmentation to improve retinal structure and function in transgenic mice
- Preclinical steps in retinal gene therapy development for rare disease
Catherine’s research centers on developing drugs and gene therapies for rare disease, with a focus on retinal gene therapy to improve vision in peroxisome disorders (PBD-ZSD). She has extensive experience forming and maintaining academic and industrial collaborations, coordinating multiple project arms, directly supervising and training students/employees, and fostering relationships with patient networks.
Striatech is a young biotech company that spun off from the University of Tübingen, Germany, at the beginning of 2018. The founders – a team of neurobiologists – are all experienced vision researchers and have made it their common goal to make innovative ideas and products from vision and behavioral research accessible to scientists worldwide.
Additional Content From Striatech
Inherited Retinal Dystrophy: Chronic Proinflammatory Signaling Accelerates the Rate of Degeneration
T.J. Hollingsworth, PhD, discusses findings from a recent study examining the effects of chronic proinflammatory signaling in inherited retinal dystrophy (IRD).
In Vivo Modeling of Immune-mediated Optic Neuropathies
Oliver W. Gramlich, PhD, provides an in-depth discussion about the pathobiology and visual phenotype of immune-mediated optic neuropathies.
Endothelial Caspase-9 Mediates Inflammatory and Vision Function Changes in Retinal Vascular Injury
Crystal Colón Ortiz, PhD, from the Columbia University Medical Center discusses the inflammatory role of endothelial caspase-9 in neurovascular injury and its contribution to vision changes.
Real-time IntraVital Microscopy (IVM): In Vivo Live Cell Imaging in Immunology and Neuroscience with Live Imaging Demo
Selina Soyeon Ahn, PhD will introduce IVIM Technology’s All-in-One real-time intravital confocal and two-photon microscopy system and its application to immunology and neuroscience research.
Fully Characterized, Standardized Human Induced Pluripotent Stem Cell Line and Ready-to-Use, High-Quality Neural Progenitor Cells for Downstream Differentiation Applications
In this webinar, experts present a standardized human induced pluripotent stem cell line and its differentiation into neural cells for disease modeling and assay development.
Peripheral and Cerebral Vascular Responses Following High-Intensity Interval Exercise
Dr. Bert Bond and Max Weston present an overview on their study investigating the effects high-intensity interval exercise has on cerebrovascular health.